Zura Bio’s (ZURA) Buy Rating Reaffirmed at Guggenheim

Zura Bio (NASDAQ:ZURA)‘s stock had its “buy” rating reiterated by research analysts at Guggenheim in a note issued to investors on Wednesday,Benzinga reports. They currently have a $15.00 target price on the stock.

A number of other brokerages have also recently commented on ZURA. Chardan Capital decreased their price target on Zura Bio from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday. HC Wainwright restated a “neutral” rating and issued a $5.00 target price on shares of Zura Bio in a research report on Tuesday, December 24th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zura Bio in a report on Wednesday, December 11th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Zura Bio presently has an average rating of “Buy” and an average price target of $15.33.

Zura Bio Stock Performance

Shares of NASDAQ:ZURA opened at $1.38 on Wednesday. Zura Bio has a 12-month low of $1.07 and a 12-month high of $6.35. The company’s 50 day moving average price is $1.49 and its two-hundred day moving average price is $2.77.

Zura Bio (NASDAQ:ZURA) last issued its quarterly earnings results on Thursday, March 27th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.09. As a group, sell-side analysts forecast that Zura Bio will post -0.65 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. increased its position in Zura Bio by 12,060.8% during the 4th quarter. JPMorgan Chase & Co. now owns 2,633,185 shares of the company’s stock worth $6,583,000 after purchasing an additional 2,611,532 shares in the last quarter. Braidwell LP acquired a new position in shares of Zura Bio during the third quarter worth $10,040,000. Geode Capital Management LLC lifted its stake in shares of Zura Bio by 4.7% in the 4th quarter. Geode Capital Management LLC now owns 955,426 shares of the company’s stock valued at $2,389,000 after acquiring an additional 42,801 shares during the last quarter. Sphera Funds Management LTD. acquired a new stake in shares of Zura Bio during the 3rd quarter valued at $2,999,000. Finally, Millennium Management LLC grew its position in Zura Bio by 1,499.0% during the 4th quarter. Millennium Management LLC now owns 701,278 shares of the company’s stock worth $1,753,000 after acquiring an additional 657,420 shares during the last quarter. Institutional investors own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.